Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the...

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Current FDA-approved imaging is insufficient for detecting prostate cancer biochemical recurrence (BCR).
• ¹⁸F-DCFPyL is a novel PET radiotracer targeting prostate-specific membrane antigen, showing high selectivity for prostate cancer cells.

Purpose of the Study:

• To evaluate the performance of ¹⁸F-DCFPyL-PET/CT for localizing prostate cancer BCR in patients with uninformative standard imaging.
• To assess the correct localization rate (CLR) and its impact on patient management.

Main Methods:

• A prospective study (CONDOR) enrolled 208 men with rising PSA levels post-treatment.
• ¹⁸F-DCFPyL-PET/CT was performed, and results were compared to a standard of truth including histopathology and correlative imaging.
• The primary endpoint was CLR, defined as positive predictive value with anatomic colocalization.

Main Results:

• The CLR ranged from 84.8% to 87.0%, exceeding the study's success criteria.
• ¹⁸F-DCFPyL-PET/CT demonstrated a disease detection rate of 59% to 66%.
• A significant 63.9% of patients experienced a change in intended management based on PET/CT findings.

Conclusions:

• ¹⁸F-DCFPyL-PET/CT successfully achieved its primary endpoint, demonstrating effective disease localization in recurrent prostate cancer.
• The findings support the clinical utility of ¹⁸F-DCFPyL-PET/CT for guiding management in patients with BCR.
• This advanced imaging modality provides clinically meaningful and actionable data for recurrent prostate cancer patients.